Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

To investigate the predictive significance of KRAS, BRAF, PIK3CA mutational status, AREG- EREG mRNA expression, PTEN protein expression and skin rash in metastatic colorectal cancer (mCRC) patients treated with cetuximab containing salvage chemotherapy. Primary tumors from 112 mCRC patients were ana...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2011-01, Vol.6 (1), p.e15980
Hauptverfasser:	Saridaki, Zacharenia, Tzardi, Maria, Papadaki, Chara, Sfakianaki, Maria, Pega, Fraga, Kalikaki, Aristea, Tsakalaki, Eleftheria, Trypaki, Maria, Messaritakis, Ippokratis, Stathopoulos, Efstathios, Mavroudis, Dimitris, Georgoulias, Vassilis, Souglakos, John
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Amphiregulin Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biomarkers, Tumor Cetuximab Class I Phosphatidylinositol 3-Kinases Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology EGF Family of Proteins Exanthema - chemically induced Exanthema - genetics Exanthema - metabolism Female Glycoproteins - analysis Humans Intercellular Signaling Peptides and Proteins - analysis Male Middle Aged Mutation Neoplasm Proteins - analysis Neoplasm Proteins - genetics Phosphatidylinositol 3-Kinases - genetics Prognosis Proto-Oncogene Proteins B-raf - genetics PTEN Phosphohydrolase - analysis ras Proteins - genetics Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To investigate the predictive significance of KRAS, BRAF, PIK3CA mutational status, AREG- EREG mRNA expression, PTEN protein expression and skin rash in metastatic colorectal cancer (mCRC) patients treated with cetuximab containing salvage chemotherapy. Primary tumors from 112 mCRC patients were analyzed. The worst skin toxicity during treatment was recorded. KRAS, BRAF and PIK3CA mutations were present in 37 (33%), 8 (7.2%) and 11 (9.8%) cases, respectively, PTEN was lost in 21 (19.8%) cases, AREG and EREG were overexpressed in 48 (45%) and 51 (49%) cases. In the whole study population, time to tumor progression (TTP) and overall survival (OS) was significantly lower in patients with KRAS (p = 0.001 and p = 0.026, respectively) or BRAF (p = 0.001 and p
ISSN:	1932-6203
DOI:	10.1371/journal.pone.0015980